Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 1998

View Archived Issues

Protein farnesyltransferase inhibitors disclosed by Schering-Plough

COX-2 inhibitors under study at Abbott

Interneuron: FY 1997 highlights

New carbapenems in development at Takeda

New antifungal antibiotic TKR-842 from Takara Shuzo

PLA2 inhibitors described by Santen

BioChem Pharma/Scriptgen conclude licensing and equity agreements

Yamanouchi: Six-month 1998 highlights

Efficacy of muscle relaxant established in preclinical models

CoCensys and MGH expand license for migraine treatment technology

Company Profile: Shaman

ABX-IL-8 slated to enter clinical testing

Heparinase III efficacy established in preclinical model

New vitamin D conjugates disclosed by Clarion

New NMDA/AMPA antagonists synthesized at Merck & Co.

Selective dopamine D3 ligands revealed by Neurogen

New AIDS treatment candidates disclosed by Vertex

New tachykinin antagonists from Schering-Plough

Arris acquisition of Sequana nears completion

FDA clears Optison

Bayer announces copromotion agreement for cerivastatin

Efficacy of recombinant hirudin demonstrated in patients with DIC

Vasoflux preclinical data presented at major hematology congress

Phase II results presented for BB-10010

Flocor enters phase I for ACS

Vical receives patent protection for lipid-mediated DNA vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...